"gp100 Melanoma Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A melanosome-associated protein that plays a role in the maturation of the MELANOSOME.
| Descriptor ID |
D058951
|
| MeSH Number(s) |
D12.776.543.306 D12.776.624.301.500 D23.050.285.439.500
|
| Concept/Terms |
gp100 Melanoma Antigen- gp100 Melanoma Antigen
- Antigen, gp100 Melanoma
- Melanoma Antigen, gp100
- gp100 Melanoma-Associated Antigen
- Antigen, gp100 Melanoma-Associated
- Melanoma-Associated Antigen, gp100
- gp100 Melanoma Associated Antigen
- ME20 Antigen
- Melanocyte Lineage-Specific Antigen gp100
- Melanocyte Lineage Specific Antigen gp100
- Melanocyte Protein Pmel 17
- Silver Locus Protein Homolog
- Melanoma-Associated Antigen gp100
- Melanoma Associated Antigen gp100
- Melanoma-Associated ME20 Antigen
- Antigen, Melanoma-Associated ME20
- ME20 Antigen, Melanoma-Associated
- Melanoma Associated ME20 Antigen
- MLSA gp100
- Pmel17 Melanoma Antigen
- Melanoma Antigen, Pmel17
- gp100 Melanocyte Differentiation Antigen
- Melanoma Antigen Glycoprotein 100
|
Below are MeSH descriptors whose meaning is more general than "gp100 Melanoma Antigen".
Below are MeSH descriptors whose meaning is more specific than "gp100 Melanoma Antigen".
This graph shows the total number of publications written about "gp100 Melanoma Antigen" by people in this website by year, and whether "gp100 Melanoma Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2006 | 0 | 4 | 4 |
| 2013 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "gp100 Melanoma Antigen" by people in Profiles.
-
Recombinant human Hsp110-gp100 chaperone complex vaccine is nontoxic and induces response in advanced stage melanoma patients. Melanoma Res. 2022 04 01; 32(2):88-97.
-
Functional cloning of a gp100-reactive T-cell receptor from vitiligo patient skin. Pigment Cell Melanoma Res. 2016 May; 29(3):379-84.
-
Renal angiomyolipoma, fat-poor variant--a clinicopathologic mimicker of malignancy. Virchows Arch. 2013 Jul; 463(1):41-6.
-
Decreased CD117 expression in hypopigmented mycosis fungoides correlates with hypomelanosis: lessons learned from vitiligo. Mod Pathol. 2006 Sep; 19(9):1255-60.
-
Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites. Cancer Immunol Immunother. 2006 Oct; 55(10):1185-97.
-
Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J Immunother. 2006 Jan-Feb; 29(1):95-101.
-
The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol. 2006 Jan 01; 176(1):157-64.
-
Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Res. 2005 Mar 01; 65(5):2009-17.
-
Recurrent melanocytic nevus: a histologic and immunohistochemical evaluation. J Cutan Pathol. 2001 Sep; 28(8):400-6.
-
Malignant melanoma with paradoxical maturation. Am J Surg Pathol. 2000 Dec; 24(12):1600-14.